Regulatory News:
Karo Bio: (STO:KARO)
The January–December period and the fourth quarter 2012 in brief
• Net sales increased to MSEK 33.2 (0.0), whereof the fourth quarter increased to MSEK 8.6 (0.0), mainly attributed to the RoRgamma deal with Pfizer
